GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » Cash Flow from Operations

Laboratory of America Holdings (Laboratory of America Holdings) Cash Flow from Operations : $1,328 Mil (TTM As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Laboratory of America Holdings Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Laboratory of America Holdings's Net Income From Continuing Operations was $-167 Mil. Its Depreciation, Depletion and Amortization was $146 Mil. Its Change In Working Capital was $225 Mil. Its cash flow from deferred tax was $-60 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $334 Mil. Its Stock Based Compensation was $27 Mil. And its Cash Flow from Others was $74 Mil. In all, Laboratory of America Holdings's Cash Flow from Operations for the three months ended in Dec. 2023 was $580 Mil.


Laboratory of America Holdings Cash Flow from Operations Historical Data

The historical data trend for Laboratory of America Holdings's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratory of America Holdings Cash Flow from Operations Chart

Laboratory of America Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,444.70 2,135.30 3,109.60 1,955.90 1,327.70

Laboratory of America Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 653.60 121.20 351.40 275.50 579.60

Laboratory of America Holdings Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Laboratory of America Holdings's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Laboratory of America Holdings's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,328 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratory of America Holdings  (NYSE:LH) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Laboratory of America Holdings's net income from continuing operations for the three months ended in Dec. 2023 was $-167 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Laboratory of America Holdings's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $146 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Laboratory of America Holdings's change in working capital for the three months ended in Dec. 2023 was $225 Mil. It means Laboratory of America Holdings's working capital increased by $225 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Laboratory of America Holdings's cash flow from deferred tax for the three months ended in Dec. 2023 was $-60 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Laboratory of America Holdings's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Laboratory of America Holdings's asset impairment charge for the three months ended in Dec. 2023 was $334 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Laboratory of America Holdings's stock based compensation for the three months ended in Dec. 2023 was $27 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Laboratory of America Holdings's cash flow from others for the three months ended in Dec. 2023 was $74 Mil.


Laboratory of America Holdings Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney officer: SVP, Chief Medical Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams director DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215